July 25, 2017 7:11 AM ET

Healthcare Equipment and Supplies

Company Overview of Angel Medical Systems, Inc.

Company Overview

Angel Medical Systems, Inc., a medical device company, develops and manufactures continuous intracardiac ischemia monitoring and alerting devices for patients and their families in Brazil. It offers AngelMed Guardian system, an implantable cardiac device designed to detect rapid ST segment changes that may signify major cardiac events, such as coronary artery occlusions caused by life-threatening vulnerable plaque ruptures. The company’s AngelMed Guardian system includes an implantable device (IMD), which detects, analyzes, and records crucial heart signal data, as well as vibrates to alert patients of cardiac events; an external device (EXD) that provides additional auditory and visual aler...

788 Shrewsbury Avenue

Suite 2144

Tinton Falls, NJ 07724

United States

Founded in 2001





Key Executives for Angel Medical Systems, Inc.

Chief Executive Officer
President & CFO
Founder & Chairman
Age: 88
Vice President of Research & Development
Vice President of Clinical & Regulatory Affairs
Compensation as of Fiscal Year 2017.

Angel Medical Systems, Inc. Key Developments

Angel Medical Systems Announces FDA Advisory Committee Meeting for Review of the AngelMed Guardian System

Angel Medical Systems Inc. has announced that the Circulatory System Devices Panel (CSDP) of the U.S. Food and Drug Administration will review the company's Premarket Approval application for the AngelMed Guardian System at a meeting on March 16, 2016. The AngelMed Guardian system is an implantable cardiac monitor, designed to detect rapid changes in the heart's electrical signal caused by a coronary artery occlusion, the precursor to a heart attack. Once an occlusion is detected, the system alerts patients to seek medical care by delivering a series of vibratory, auditory, and visual warnings. The Advisory Committee will review data submitted in the PMA from the pivotal study of the Guardian System called ALERTS. This trial was a randomized, prospective study of 907 high-risk subjects who had experienced a previous heart attack or acute coronary syndrome event. All subjects were implanted with the Guardian System and assigned to have the alerting feature of the device either turned on or off for a 6-month period to assess whether Guardian System alerts reduced the composite incidence of death, new Q-wave myocardial infarction, or late presentation for thrombotic coronary occlusion events. In conjunction with the scheduling of the CSDP meeting, Angel Medical also received the final $10 million tranche of a milestone-based $40 million convertible note financing that had its initial closing in 2012.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Angel Medical Systems, Inc., please visit www.angel-med.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.